by Barry101 | Apr 4, 2018 | Press Release
Early Access Programs are Known as “Special Access Programme” in CanadaORLANDO, Fla., April 04, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, said it amended its agreement with Netherlands-based...
by Barry101 | Apr 2, 2018 | Press Release
ORLANDO, Fla., April 02, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on immuno-pharmaceutical research and the commercial development of its immunology products Ampligen® and Alferon®, announced its financial results for the year...
by Barry101 | Mar 14, 2018 | Press Release
Study Combines Ampligen Drug, Peptide Vaccine in Attempt to Enhance Immune SystemORLANDO, Fla., March 14, 2018 — The University of Nebraska Medical Center and Hemispherx Biopharma, Inc. (NYSE American:HEB) are joining forces to take on pancreatic cancer, one of...
by Barry101 | Mar 5, 2018 | Press Release
ORLANDO, Fla., March 05, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the 30th Annual ROTH Conference on Monday, March 12th at 5:30PM PT in Green – Salon 3 (the...
by Barry101 | Feb 27, 2018 | Press Release
ORLANDO, Fla., Feb. 27, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on pharmaceutical research, announced today that it will be presenting at the inaugural LD Micro Virtual Conference on Wednesday, March 7, 2018 at 10:00 AM PST. Thomas K....
by Barry101 | Feb 26, 2018 | Press Release
Agreement with myTomorrows, Following Success in Netherlands, Seeks to Expand Ampligen Early Access Programs in Pancreatic Cancer into CanadaORLANDO, Fla., Feb. 26, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) said it is expanding its partnership with...
